Global Research at UCSF
contact info
  • Resources
    • About the Forum
    • UCSF Programs
    • Scholars Resource Center
    • Partners Abroad
    • UCSF Affiliated Organizations
  • Admin Forum
    • Health/Insurance Forum
    • Grant Management Forum
    • Connectivity Forum
    • IRB Forum
    • Budgeting Forum
    • Shipping forum
  • Interest Group
    • Alcohol and HIV Interest
    • East Africa Interest Group >
      • Kenya Forum
      • Tanzania Forum
      • Uganda Forum
    • Global Health Economics
    • Global Hospitalists
    • Global Maternal & Newborn
    • Global Nursing
    • Global Oncology
    • Global Oral Health
    • Global Pediatrics Interest
    • Global Surgery
    • Global Vision
    • India Interest Group >
      • India/Southeast Asia
    • Infectious Disease Implementation Science
    • Diagnostics
    • Disaster Response
    • Refugee Health
    • Malaria Interest
    • Young Investigators in International Research
  • Work Group
    • UCSF East Africa Scientific Meeting
    • East Africa Office
    • Global JrFaculty
    • International Research Advisory Committee
    • Travel Health & Safety
    • GHS Alumni
  • Newsletter

Trisha Hue

10/18/2014

2 Comments

 
Picture
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic Acid. Studies have shown that bisphosphonates may have antitumor and antimetastatic properties. Recently, observational studies have suggested a possible protective effect of bisphosphonates on breast cancer, but the effect of bisphosphonate use on risk of breast cancer has not been tested in randomized trials.
OBJECTIVE: To assess the relationship of postmenopausal breast cancer incidence and bisphosphonate use using data from 2 randomized (1:1), double-blind, placebo-controlled trials.
DESIGN, SETTING, AND PARTICIPANTS: The Fracture Intervention Trial (FIT) randomly assigned 6459 women aged 55 to 81 years to alendronate or placebo for a mean follow-up of 3.8 years. The Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT) randomly assigned 7765 women aged 65 to 89 years to annual intravenous zoledronic acid or placebo for a mean follow-up of 2.8 years. Data were collected at clinical centers in the United States (FIT and HORIZON-PFT) and in Asia and the Pacific, Europe, North America, and South America (HORIZON-PFT). Women, in either study, with recurrent breast cancer or who reported a history of breast cancer were excluded from analyses. In each trial, a blinded review was conducted of each cancer adverse event report to verify incident invasive breast cancer cases. The primary analysis compared events in the active vs placebo group using a log-rank test.

2 Comments
grabessay.com link
1/8/2015 04:56:40 pm

Composing expositions are the penmanship where an author expounds on any theme or embrace to furnish a proportional payback or considered that subject into the compositions. Here we make up accessible data about article written work. To recognize subtle elements please visit our site.

Reply
obat kuat link
10/18/2017 05:30:55 am

jos pokok e

Reply



Leave a Reply.

    Author

    GlobalResearch at UCSF presents the broad scope of health research that is being conducted by UCSF researchers worldwide

    Archives

    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013

    Categories

    All
    HIV

    RSS Feed

UCSF Global Projects worldwide

Picture
Learn about UCSF Research across the globe.

UCSF Global Health Sciences (GHS)

Picture
UCSF Global Health Sciences
Our mothership.

Picture

Travel Health & Safety links

Picture

UCSF Global HUB

Picture
Compliance & logistics for global research

CTSI- Global Health Program

Picture
Tap into expertise at UCSF

✕